Thursday, July 2, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
MARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big TechtodayHEALTHCARE340B Under Fire: The Hospital Drug Discount Fight That Hits CVS and HCA Where It Hurts4 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets PaidtodayHEALTHCAREGLP-1 Coverage Mandate: The Federal Obesity Drug Windfall for Lilly and Novo4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger MarkettodayHEALTHCAREFDA Accelerated Approval Reform: The Vertex Model Every Biotech Wants4 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending BoomtodayHEALTHCAREThe Medicare Drug Negotiation Trade: Who Gets Hurt When Washington Sets the Price4 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real MoneytodayCRYPTOThe Anti-CBDC Play: No Digital Dollar Means Private Rails Win4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is MovingtodayCRYPTOThe Toll Booth at the Top of the Bitcoin ETF Stack4 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet TailwindtodayCRYPTOThe IRS Closes the Crypto Wash-Sale Loophole — and Robinhood Collects the Toll4 weeks agoDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company ForevertodayCRYPTOThe Debanking Era Is Over. HOOD and Block Are Next in Line at the Window.4 weeks agoTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic ProducersyesterdayCRYPTOMining the Grid: How EPA and Energy Policy Set the Spread for Proof-of-Work Miners3 weeks agoTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to WatchyesterdayCRYPTOThe Stablecoin Bill: Who Controls the On-Ramp When Congress Licenses It3 weeks agoMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More PoliticalyesterdayCRYPTOBitcoin as Reserve Asset: The Federal Legitimacy Trade3 weeks agoDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In SpendingyesterdayCRYPTOThe SEC Retreat: How a Friendlier Regulator Unlocks Coinbase's Business Model3 weeks agoDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Trade2 days agoTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware3 weeks agoDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation3 days agoTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge3 weeks agoDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream3 days agoTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think3 weeks agoDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It4 days agoTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron3 weeks agoDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program5 days agoTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map3 weeks agoDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes5 days agoTECHThe Chip Stack Below the Pentagon's AI Buildup3 weeks agoENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil6 days agoTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion3 weeks agoENERGYLNG Export Licenses: How a FERC Approval Mints a Monopolylast weekENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers2 weeks agoENERGYThe BLM Calendar That Moves COP and OXYlast weekTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two2 weeks agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Giftlast weekENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom2 weeks agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keyslast weekENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear2 weeks agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deductionlast weekENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch2 weeks agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economicslast weekENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade2 weeks agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hublast weekENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactorslast weekENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alivelast weekENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centruslast week
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

FDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Market

Lowering the age threshold for the first CRISPR gene therapy meaningfully expands the addressable patient pool.

Image: Money Racket
By at Money Racket · Jul 2, 2026

The FDA granted supplemental approval for Casgevy (exagamglogene autotemcel) in patients aged 2 and older with sickle cell disease or transfusion-dependent beta thalassemia. Previously approved only for patients 12 and older, the label expansion opens the therapy to a substantially younger — and larger — patient population.

Who cashes in: Casgevy is co-owned by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP). Vertex handles commercialization and books the majority of revenue; CRISPR Therapeutics receives royalties and milestone payments. The younger age label matters because sickle cell disease causes cumulative organ damage from early childhood — earlier intervention is clinically compelling, which means physicians have stronger motivation to prescribe. The addressable patient pool in the U.S. alone roughly doubles when you include pediatric patients under 12. bluebird bio (BLUE) has a competing gene therapy (Lyfgenia) for sickle cell, so the Casgevy expansion also pressures bluebird's already-thin market position.

Dropping the age floor from 12 to 2 doesn't just expand a label — it roughly doubles the number of patients who could qualify for a $2.2 million therapy.

Who's exposed: bluebird bio (BLUE) is the clearest loser. Its Lyfgenia therapy uses a different mechanism (lentiviral vector vs. CRISPR) and has faced reimbursement headwinds. A broader Casgevy label makes the competitive dynamic harder. Hydroxyurea manufacturers and chronic transfusion programs face long-term volume pressure as gene therapy becomes accessible earlier in a patient's life.

What to watch next: Payer coverage decisions for the pediatric population. Casgevy's list price is approximately $2.2 million per patient — insurers have been slow to cover it even for adults. If major payers extend coverage to the 2-11 age group, that's when the revenue expansion becomes real.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →